Olga S. Matlin, PhD

The authors examined trends in the utilization of prescription opioid medication following introduction of abuse deterrent technology for Oxycontin.

We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.

With new drugs in the pipeline and the impact of updated FDA drug safety policies on colchicine, gout may no longer be inexpensive to treat.

Generic atorvastatin led to an increase in generic dispensing rate and a reduction in the cost of treatment for patients requiring cholesterol-lowering treatment. The upcoming introduction of the PCSK9 inhibitor may change this trend.

Multiple sclerosis (MS) is of interest because it is one of the most costly neurological diseases and the introduction of the first oral treatments in 2010 amplified high treatment costs of MS even further.

Based on American College of Rheumatology recommendations and novel emerging treatment options, the trend of increasing biologic use for rheumatoid arthritis is expected to continue.

HIV is of interest among many in managed care. This paper focuses on the costs and demographic characteristics associated with new HIV therapy initiators.